This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk05: Good afternoon, ladies and gentlemen, and welcome to the Zynex first quarter 2023 earnings conference call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to Louisa Smith from the Gilmartin Group.
spk00: Thank you, Jason, and good afternoon, everyone. Earlier today, Zynex released financial results for the first quarter ending March 31st, 2023. A copy of the press release is available on the company's website. Joining me on today's call are Thomas Vanguard, Chairman, President, and Chief Executive Officer, Dan Moorhead, Chief Financial Officer, Anna Lusak, Chief Operating Officer, and Donald Gregg, President of Zynex Monitoring Solutions. Before we begin, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's 2022 Form 10-K and subsequent Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, product potential, the regulatory environment, sales and marketing strategies, capital resources, or operating performance. With that, I'll now turn the call over to Thomas.
spk03: Thank you, Louisa, and good afternoon, everyone. Thank you for joining us today for the first quarter 2023 earnings call. We had another impressive period of growth, and we've now been profitable in 26 of the last 27 quarters. And we once again hit the highest number of prescriptions in the company's history, beating the records we previously set in the second, third, and fourth quarters of 2022. Additionally, we were able to increase order numbers over Q4 despite the seasonal reset in deductibles that typically limits growth of orders in the beginning of the year. Total revenue for the quarter was $42.2 million, a 36% increase over the same period in 2022, and we produced in earnings $0.04 per share. Our sales force is maintaining the exceptional trends in productivity and expanding our market share significantly each quarter, a testament to both efficiency and our product's efficacy. Orders increase 61% year-over-year, and we believe that there is considerable runway for us to continue growing orders into the future. In the first quarter, we completed the latest in a series of stock buybacks, and repurchased $3.4 million worth of common stock, bringing the total of repurchases in the last year to $30 million. As we've stated before, I believe this to be a signal to our shareholders that we are incredibly confident in our management teams, the growth opportunities in both divisions, and that we remain committed to creating shareholder value in the near and long term. In addition to the impressive results from our pain management division, our monitoring solutions division is making excellent strides in the development of our blood and fluid monitor and our laser-based pulse oximeter. Don Greig will provide further updates in his prepared remarks, but I'm pleased with the steps the growing team is taking to bring those game-changing products to market. Monitoring Solutions has grown significantly over the past year, and after having acquired Kestrel Labs in December of 2021, we've been working diligently on clinical data collections and reaching regulatory milestones. Cynics continues to deliver consistent results, and even with investments in the monitoring division, our pain management business has been able to maintain profitability at the bottom line, for the combined entity. Our ability to execute operationally and strategically while diversifying the business into compelling market opportunities is evidenced by the double-digit growth we've seen year after year. I look forward to announcing future catalysts and growth opportunities throughout 2023, and I'm thrilled with our performance to date. With that, I will now turn the call over to Anna Luksock, our chief operating officer, for a more detailed business update on the pain management division.
spk01: Thank you, Thomas. Dynex's pain management division had another impressive quarter marked by a sequential increase in order volumes over the fourth quarter and a 36% year-over-year increase in revenues. The growth that our sales team is delivering is consistent and profitable, and we believe there's significant room for continued expansion to reach full market penetration. We ended the first quarter with approximately 460 sales reps and revenue per rep on an annualized basis with approximately 380,000, an increase of 24% over the first quarter of 2022. Sales rep productivity remains the primary area of emphasis in our sales organization. Our new hires are incorporated into the organization more quickly and the sales management structure we've implemented is optimizing performance across the board. There are some lingering challenges related to the labor market, but we believe these to be improving over time, and we will remain committed to recruiting and retaining a high-quality sales and corporate team. We'll continue to expand into additional sales territories and expect to hit approximately 525 to 550 sales reps by year-end to capitalize on growing orders. Our collections remain strong throughout the quarter, and we would like to reiterate that we have and we will continue to work with all payer types and insurance providers. We believe this to be a key differentiator between Xynex and some other competitors in the market, as practitioners are able to prescribe our product to all patients in pain, not just a small cohort under specific insurance plans. We process all orders that we receive and work directly with patients and their insurers to process coverage in each case. I look forward to another profitable year for the Pay Management Division and updating you all on our market extensions on future calls. I'll now ask Don Gregg, President of Zymex Monitoring Solutions, to provide updates related to that business division.
spk08: Thank you, Anna. Xynex Monitoring Solutions is developing a strategic product portfolio and pipeline to address a nearly $4 billion market in the patient monitoring space. Our initial products will cover hemodynamic monitoring, sepsis monitoring, and laser-based pulse oximetry. As Thomas mentioned previously, our team has grown significantly in the last year, and we're invested substantially in the division as we make progress towards clinical and regulatory milestones. Of the two product lines we are actively developing, the CM1600 blood and fluid monitor is going to be the first in our go-to-market strategy, as it's the furthest along in its regulatory pathway. The hemodynamic monitor is a non-invasive wireless blood and fluid monitor to be used in a hospital setting. The previous generation device, the CM1500, has already received clearance from the FDA, and we've added a wireless capability to the CM1600. The CM-1600 was submitted to the FDA, and we are anticipating further details from the agency as we are currently engaged in an interactive review with them. As a reminder, Xynex is not contemplating any revenue from the monitoring division and its guidance for 2023. Additionally, in development are the NECO, or also known as the non-invasive co-oximeter, and the Hemox pulse oximeter, both non-invasive laser technologies. We believe that this innovative technology will replace the less accurate LED-based legacy devices that are currently used today. We are on track for a NICO submission to the FDA in Q4 2023 and actively running clinical trials. In addition to engineering and development advancements within the division, we are also involved in planning, enrolling, and publishing numerous clinical trials to include hundreds of subjects across the country. We've seen encouraging results on product efficacy thus far and remain confident with the market opportunity for the disruptive technology. As we publish further data, we will advise the investment community via press releases and on future quarterly calls. I'm excited to be a part of what should be a notable inflection point in the monitoring division over the next 18 to 24 months and look forward to leveraging our innovative technology in the market. I will now turn the call over to Dan Moorhead Chief Financial Officer for a more in-depth look at the financial performance for the quarter.
spk09: Thanks, Don. Please refer to our press release issued earlier today for a summary of our financial results for the first quarter of 2023. After commenting on the financial results, Thomas will review our guidance for 2023. Orders grew 61% year-over-year, and net revenue grew 36% to $42.2 million. from 31.1 million in 2022. Device revenue increased 78% to 11.9 million compared to 6.7 million in the first quarter last year. Supplies revenue increased 24% year-over-year to 30.2 million from 24.4 million, and gross margin was 78% in the first quarter. Sales and marketing expenses were $21.2 million in the first quarter of 2023 compared to $14.4 million in the same period in 2022. G&A expenses were $11.4 million in the first quarter of 2023 compared to $7.8 million last year. Approximately 20% of the increase in G&A is related to investments in our monitoring solutions division and related headcount to launch our new products. The remainder is primarily for back office headcount related to order growth. Tax expense as a percentage was a 2% effective rate for the quarter due to other income of $1.4 million. Net income grew 14% year-over-year to $1.6 million and produced 4 cents per diluted share in the first quarter of 2023. We ended the quarter with $16.8 million in cash. Cash flow from operations in the quarter increased 10% year-over-year to $1.9 million. I'll now turn the call back over to Thomas.
spk03: Thank you, Dan. We grew orders in the fourth quarter of last year by 48% year-over-year. It increased to 61% in the first quarter of the year. And here in the beginning of the second quarter, we've already had a strong start in terms of orders and expect to post our fifth consecutive record quarter. With the continued growth in orders in the second quarter of 2023, we expect total revenue between 43.5 and 45.5 million, which is approximately 21% greater than the second quarter of 2022. And we expect to see earnings per share between 3 and 7 cents. As for our 2023 outlook, we are reiterating our initial guidance and expect total revenue to be in the range of 180 to 200 million, representing growth of approximately 21% over 2022, and earnings per share of approximately 40 to 50 cents. With that, operator, please open the call up for questions.
spk05: We will now begin the question and answer session. To ask a question, you may press star, then one on your touchtone phone. If you're using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star, then two. At this time, we'll pause momentarily to assemble our roster. Our first question comes from Jeffrey Cohen from Lattenburg-Tholman. Please go ahead.
spk06: Hi, Thomas, Stan, and Donald. How are you?
spk03: We're all great.
spk06: Awesome.
spk03: You can't go along with numbers like that, right?
spk06: Yeah, that's right. So congrats on the quarter. Looks very strong. Just a couple questions from Aaron. I guess firstly... You're still feeling pretty optimistic on 1600 and timeline to approval. Are we still hopeful about back half of the year? Or closer?
spk08: This is Don. We are definitely feeling confident. As I mentioned, we're in the interactive review with the FDA. So it's been a bit of a back and forth. We, in those discussions, have... had an opportunity to ensure that the FDA feels comfortable with the device and the technology. And so I'll reiterate, our plans at this point are the same.
spk06: Got it. OK, that's helpful. Maybe hypothesize with us how you're thinking about commercial strategies and direct, non-direct from a commercial standpoint into next year. Yeah.
spk08: I think we mentioned before that we would have a direct and an indirect sales team. We will grow that slowly as we enter the market. This is a brand-new market, essentially, in which requires some market development, so we have some placement of devices that we will need to do and certainly prove out the technology to clinicians, et cetera. Get closer to our products on the NICO non-invasive co-oxymeter. That's a fairly defined market. And so our strategy there is slightly different. And so as I had mentioned previously, we will be submitting to the FDA later in the year on that device. And we're actively running clinical trials here between now and the back half of the year.
spk06: Okay. Hemox, will that also get filed, submitted later this year?
spk08: That will not be submitted later this year, but we are working on the technology. So the laser technology applies to both the pulse or the co-oximeter and to Hemox. And Hemox will bring different technology and parameters to the market. meaning that you'll have total hemoglobin and other parameters like that with Hemox. Okay, got it.
spk06: And I guess a question for Anne as far as the sales force and growth. It sounds like it will be linear throughout the year, kind of on par with Q1, or is there a bolus coming through earlier or later?
spk01: The growth will be in line with Q1. We'll continue to grow our orders throughout the year.
spk03: And the number of sales folks.
spk09: Sales reps will be fairly linear, Jeff.
spk06: Okay. Got it. And then lastly, congrats on the buybacks at $8.82 on average. What's the share count now? I see 37.44. Is that diluted currently? And the buybacks have concluded with none open today.
spk09: We are, yeah, diluted for the, well, diluted outstanding was 37.4. The other figure will be in the press release as well, the actual numbers here and then in the queue. But, yeah, we do not currently have a buyback that is open right now.
spk06: Okay. Got it. I think that does it for us. Thanks for taking the questions.
spk05: The next question comes from Adam Ater from Piper Sandler. Please go ahead.
spk02: Hi, good afternoon. Thank you for taking the questions and congrats on the nice start to the year. Wanted to start with the Salesforce update. If I heard correctly, the new target is 525 to 550 by year end. I think before you were aiming closer to 550. You know, and I think you're at 460 exiting Q1. So just curious, you know, are you seeing something kind of, you know, change from a hiring environment standpoint? Did you see any attrition in the quarter? And then maybe just also talk about level of confidence in delivering against the top line outlook and any dependence there kind of hitting the headcount target.
spk04: Thanks.
spk01: Yes, so there are not a lot of changes in the hiring market. The hiring market is improving as we're seeing it, but obviously we can't speak with confidence on how the remainder of the year is going to go. We are a lot quicker with exiting underperformers out of the organization, and we'll continue focusing on that throughout the year.
spk02: Okay, so nothing, I guess, as it relates to Q1. There's no issue with attrition of reps. It was maybe you just hired a little bit more slowly than expected. Is that a fair conclusion?
spk09: I saw timing a little bit too, Adam. Some people start right after the end of the quarter and, you know, Throughout the year, obviously, at quarter cutoffs, it can be a little misleading at times, but we've seen a pretty good hiring cadence and had a pretty good group come in in April as well. So I think we're pretty comfortable with the numbers. And we gave a range, you know, the 525 to 550, but, you know, we think that's very achievable.
spk02: Okay. Okay, perfect. No, that's helpful, Culler. I appreciate that, Anna and Dan. And then I guess for the follow-ups, I wanted to ask about NECO. And if I heard correctly, Q423, FDA submission. You know, anything you guys can share at this point in terms of the clinical performance or learnings from the clinical studies that you've run? You know, how do we think about, you know, likelihood of approval or any potential clinical risk? And then I have one follow-up. Thanks.
spk08: Sure. This is Don. I will take that question. We have been running bench studies, and those are internal studies at this point in time. We have a clinical study that's starting here in May at a clinical trial site. In the pulse oximetry market, there's an FDA guidance document that pretty clearly outlines that you've got to run certain human studies on your hypoxia and calibration and verification. And so we're starting all of those. The performance of the device is significantly more accurate at this point than what we were expecting. We're seeing ranges of accuracy higher than legacy devices that you see on the market today based on LED technology. And so we believe that Our submission is definitely on track for Q4. We're trying to hit the earlier part of Q4 at this point in time, but certainly given guidance that it's going to be submitted to the FDA in the Q4 timeframe.
spk02: That's great color, Don. Thank you for that. And then maybe just one last one for me, and I'll jump back in queue. It relates to just the The guidance range, the full-year EPS guidance, was hoping you could just bridge us a little bit, you know, to that range. It looks like it implies a little bit of a healthy ramp in the back half of the year to kind of get to the, you know, the bottom or the midpoint. So just broad strokes, Dan, can you just talk through kind of the cadence of spend and I guess, you know, any color on the top line cadence as well. Thanks so much for taking the questions and congrats again on the start to the year.
spk09: Yeah, no, I think, again, top line, we're tracking, you know, orders have been strong, 61%. We expect that to continue. On the spend, you know, I think, you know, it'll continue to grow, obviously, on the sales and marketing line as we grow the territory managers and Other pieces there, you know, commissions and other things that are variable based on number of orders. And then on the DNA side, most of that's going to be around the size. But the ramp is going to be similar to what it was last year. You know, last year. The majority, well over the majority, was in the second half of the year, and that will continue this year. So I think, you know, the four cents we did in Q1, I think consensus for Q2, 3, and 4 are similar with the numbers you guys have out there, and that gets us right there.
spk04: Thanks so much for the color. Our next question comes from Yi Chen from H.C. Wainwright. Please go ahead. Thank you for taking my questions. Hi.
spk07: Could you comment on whether you observed that the productivity of the sales team increased proportionally to the increase in orders?
spk09: So we said, you know, the increase in sales productivity was up about 24% and orders were up 61%. You just got to remember Orders will recognize revenue over a period of, you know, we generally say six to nine months. So there's always going to be a lag there. So we were pleased with, you know, the revenue increase, obviously, and the order increase. But the revenue obviously means we're turning that into cash and growing the top line.
spk07: Okay. Could you discuss in your opinion what are the key factors that would ensure a successful launch trajectory for the fluid monitor?
spk08: Yes, this is Don again. I think that for us, adoption in the market by key clinical opinion leaders is very important. The way that our technology works is quite different than other monitors in that space at this point in time. Significantly, products in that area are somewhat, I would call, more invasive or minimally invasive, and ours is certainly based on non-invasive technology. We will ensure that we communicate effectively to key opinion leaders. We've been doing that throughout the development and have many of them on board with us to understand the technology. We also run a number of clinical trials in several different ways to demonstrate and exercise the effectiveness of the device. And so that is a key entry. As I mentioned previously on the call, that this is a new market that requires a lot of market development. And adoption of this technology is very important from a clinical standpoint.
spk07: Okay, thank you.
spk05: This concludes our question and answer session. I would like to turn the conference back over to Thomas Sandgaard for any closing remarks.
spk03: Thank you for joining us today. We are pleased with our performance this quarter and the consistent growth our team is delivering. We look forward to leveraging that momentum throughout the rest of the year and to speaking to you at upcoming investor events. We appreciate your time and interest in Sinex. Have a great day.
spk05: The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.
Disclaimer